Project partner DGK has published a short article in Cardio News introducing the SGLT2 HYPE study and its ambition to investigate whether dapagliflozin can improve cardiovascular and renal outcomes in people with hypertension and high cardiovascular risk.
The article highlights the study’s scientific rationale, patient-centred approach and potential to open up a new evidence-based treatment option for hypertension.
Read the full article to learn more about the aims and significance of SGLT2 HYPE.
